Press Releases

Measuring the Bone Scan Index (BSI) is a strong complement to PSA

EXINI Diagnostics AB
Investor News

Measuring the Bone Scan Index (BSI) is a strong complement to PSA

Lund, Sweden, 2013-03-04 09:22 CET (GLOBE NEWSWIRE) --

Measuring the Bone Scan Index (BSI) on high risk patients with prostate cancer,
can provide important information on survival, and is a strong complement to
Prostate-Specific Antigen (PSA). This is shown in a recently published Swedish
study.

In 2012, a number of studies have been published, showing the usefulness of the
unique BSI value, calculated by the software EXINI bone. To these, another
article is added, published in EJNMMI Research. This retrospective study from
Sahlgrenska University Hospital in Gothenburg, Sweden, shows that the BSI
measured at the occasion of diagnosis is a valuable add-on in order to
risk-stratify high-risk patients with prostate cancer who underwent primary
hormonal treatment.

Kaboteh R, et al. "Bone Scan Index: a prognostic imaging biomarker for
high-risk prostate cancer patients receiving primary hormonal therapy." EJNMMI
Research 2013, 3:9 doi:10.1186/2191-219X-3-9.

Conclusion: "BSI can be used as a complement to PSA to risk-stratify high-risk
prostate cancer patients at the time of diagnosis. This imaging biomarker,
reflecting the extent of metastatic disease, can be of value both in clinical
trials and in patient management when deciding on treatment."

BSI is an automatically measured imaging biomarker, which gives a quick and
objective measure on the extent of the total skeleton that is inflicted by
metastases. The current study, "Bone Scan Index: a prognostic imaging biomarker
for high-risk prostate cancer patients receiving primary hormonal therapy"
shows the BSI-value’s strong connection to survival. The conclusion is that BSI
adds further prognostic information in addition to the traditional measuring
tools at hand, e.g. PSA.

- The results confirm earlier studies, and gives us further evidence that BSI
adds new information. It gives quick and important guidance, which is valuable
both in clinical routine, as in research, says Lars Edenbrandt, Scientific
Director & Founder of EXINI Diagnostics AB

For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision
support to hospitals worldwide. The system is based on advanced image analysis
by artificial intelligence and can make its own interpretation of radiology
images and provide diagnostic suggestions. In this way the system is used as a
decision support for the diagnosing doctor. EXINI is working with products for
the diagnosis of some of the most frequent endemic diseases such as coronary
heart disease, cancer, dementia and Parkinson's disease. The company was
founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock
market NASDAQ OMX First North and has about 400 shareholders. Principal owner
is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.

________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70
Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,
www.exini.com


Relaterade filer

1 https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=421476
© Copyright Carnegie Investment Bank AB 2018. All rights reserved.